64.23
Boston Scientific Corp stock is traded at $64.23, with a volume of 12.09M.
It is up +1.28% in the last 24 hours and down -9.79% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
See More
Previous Close:
$63.42
Open:
$64.08
24h Volume:
12.09M
Relative Volume:
0.74
Market Cap:
$95.46B
Revenue:
$20.08B
Net Income/Loss:
$2.89B
P/E Ratio:
33.12
EPS:
1.9391
Net Cash Flow:
$3.66B
1W Performance:
+3.95%
1M Performance:
-9.79%
6M Performance:
-35.28%
1Y Performance:
-32.47%
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, SYK, MDT, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
BSX
Boston Scientific Corp
|
64.23 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
ABT
Abbott Laboratories
|
96.81 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
|
SYK
Stryker Corp
|
343.32 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
86.19 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
|
EW
Edwards Lifesciences Corp
|
80.99 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-26 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-03-25 | Downgrade | Erste Group | Buy → Hold |
| Sep-08-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-16-25 | Initiated | Leerink Partners | Outperform |
| Apr-16-25 | Upgrade | Needham | Hold → Buy |
| Jan-10-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
ROSEN, THE FIRST FILING FIRM, Encourages Lufax Holding Ltd Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Boston Scientific Advances Fainting Detection Study With New Wearable Data Initiative - TipRanks
Boston Scientific Corporation $BSX Position Lifted by Ninety One UK Ltd - MarketBeat
Asset Management One Co. Ltd. Increases Stock Position in Boston Scientific Corporation $BSX - MarketBeat
AE Wealth Management LLC Boosts Stake in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific Corp Investor Event at the Scientific Session of the American College of Cardiology Transcript - GuruFocus
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class ActionBSX - TMX Newsfile
Boston Scientific Corp. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Boston Scientific Corporation (BSX) Price Target Lowered at Mizuho Ahead of Q1 Medical Device Earnings - Insider Monkey
Boston Scientific (BSX) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance
Boston Scientific: The Company That Never Turned Around - Yahoo
Analysts Bullish on Boston Scientific (BSX) Amid Expectations for 30% YoY Growth in 2026 - Insider Monkey
INVESTOR DEADLINE: Boston Scientific Corporation (BSX) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - PR Newswire
BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting Electrophysiology Procedure Growth - marketscreener.com
Boston Scientific Corporation $BSX Position Increased by KBC Group NV - MarketBeat
Boston Scientific (BSX) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Boston Scientific Corp. stock outperforms competitors on strong trading day - MarketWatch
BSX Investors Have Opportunity to Lead Boston Scientific Corporation Securities Fraud Lawsuit - ChartMill
Boston Scientific Corp (BSX-N) Stock Price and News - The Globe and Mail
Truist cuts Boston Scientific stock price target on Watchman concerns By Investing.com - Investing.com South Africa
Truist cuts Boston Scientific stock price target on Watchman concerns - Investing.com
BSX Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026 - marketscreener.com
Truist Financial Cuts Boston Scientific (NYSE:BSX) Price Target to $90.00 - MarketBeat
Boston Scientific (BSX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Baird Adjusts Boston Scientific Price Target to $86 From $95, Maintains Outperform Rating - marketscreener.com
Truist Trims Price Target on Boston Scientific to $90 From $92, Keeps Buy Rating - marketscreener.com
Boston Scientific invests €75m in Galway site - Business Post
Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Barchart.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines – BSX - ChartMill
Boston Scientific Corp. stock rises Tuesday, still underperforms market - MarketWatch
Cardiac Monitoring Devices Market Set for Sustained Growth at 5.17% CAGR Through 2034: DelveInsight | Philips, Medtronic, and Boston Scientific - Barchart.com
Citi Reiterates Buy rating for Boston Scientific (BSX) - Yahoo Finance
Boston Scientific Corp. stock (US10117L1017): Is medtech innovation strong enough to unlock new upsi - AD HOC NEWS
BOSTON SCIENTIFIC CORPORATION (BSX) DEADLINE ALERT Bernstein Liebhard LLP Reminds Boston Scientific Corporation Investors of Upcoming Deadline - TMX Newsfile
Fund Update: 486,715 BOSTON SCIENTIFIC (BSX) shares added to Bank Pictet & Cie (Europe) AG portfolio - Quiver Quantitative
BSX Shareholder Alert: Boston Scientific Corporation Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm - Barchart.com
RBC Cuts Price Target on Boston Scientific to $105 From $115, Keeps Outperform Rating - marketscreener.com
Faruqi & Faruqi, LLP Highlights Class Action Against Boston Scientific (BSX) and Upcoming Lead Plaintiff Deadline of May 4, 2026 - marketscreener.com
Will Boston Scientific (BSX) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Portnoy Law Firm Announces Class Action on Behalf of Boston Scientific Corporation Investors - GlobeNewswire
BSX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026 - marketscreener.com
Sumitomo Mitsui Trust Group Inc. Trims Stock Position in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific Corporation $BSX Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Boston Scientific Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
Boston Scientific Corporation $BSX Shares Sold by Massachusetts Financial Services Co. MA - MarketBeat
Boston Scientific Corp. stock (US10117L1017): Is its medtech innovation edge strong enough to drive - AD HOC NEWS
BSX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026 - marketscreener.com
Sowell Financial Services LLC Sells 21,713 Shares of Boston Scientific Corporation $BSX - MarketBeat
Why Boston Scientific's big dip could be a bigger opportunity - MSN
BSX Price History for Boston Scientific Corp Stock - Barchart
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):